Loading organizations...

Ceptaris Therapeutics is a technology company.
Ceptaris Therapeutics develops and commercializes specialty pharmaceutical products for oncology. Its primary innovation is a proprietary gel formulation of mechlorethamine hydrochloride, specifically designed for topical treatment of early-stage (stages I-IIA) mycosis fungoides. This localized delivery system provides a targeted therapeutic approach for patients with cutaneous T-cell lymphoma.
Established in 2001, Ceptaris Therapeutics was founded to address unmet needs in oncology, particularly rare skin cancers. The company focused on developing specialized formulations to enhance drug delivery and improve patient outcomes. Its inception re-envisioned known active pharmaceutical ingredients through advanced proprietary systems.
Ceptaris Therapeutics' products serve patients diagnosed with early-stage mycosis fungoides requiring localized treatment. The company's vision centered on bringing innovative, targeted therapies to market, striving to improve lives affected by dermatological cancers. They aimed to advance specialized oncology care.
Ceptaris Therapeutics has raised $54.0M across 4 funding rounds.
Ceptaris Therapeutics has raised $54.0M in total across 4 funding rounds.
Ceptaris Therapeutics has raised $54.0M in total across 4 funding rounds.
Ceptaris Therapeutics's investors include Frazier Healthcare Partners, Aperture Venture Partners, BioAdvance, Burrill & Company, Osage Venture Partners, Palo Alto Investors, Third Point, Vivo Ventures, Oxford Finance, Silicon Valley Bank.
# Ceptaris Therapeutics: A Specialty Pharmaceutical Company, Not a Technology Company
The premise of your query contains an inaccuracy: Ceptaris Therapeutics is a specialty pharmaceutical company, not a technology company.[1][2] It develops proprietary drug formulations for rare diseases rather than building software, hardware, or digital platforms.
Ceptaris Therapeutics is a specialty pharmaceutical company focused on developing treatments for rare cancers, specifically cutaneous T-cell lymphomas (CTCL).[1][2] The company's primary product is Valchlor, a proprietary gel formulation of mechlorethamine designed to treat early-stage mycosis fungoides, a type of CTCL.[1]
The company serves patients with rare skin cancers who lack effective topical treatment options. Its core mission is to revolutionize treatment for early-stage mycosis fungoides by offering the first topical mechlorethamine product available for this indication.[2] Ceptaris operated as an independent entity until August 2013, when it was acquired by Actelion Pharmaceuticals, a Swiss pharmaceutical company listed on the SIX Swiss Exchange.[1]
Ceptaris was established in 2002 in Malvern, Pennsylvania.[4] The company was founded with the specific objective of developing a novel topical formulation of an existing chemotherapy agent (mechlorethamine) for a rare cancer indication where treatment options were limited.
The company gained traction through venture capital funding, securing $15 million in February 2012 through Oxford Finance and Silicon Valley Bank, followed by $10 million in Series D-1 funding in June 2012 from investors including Aperture Venture Partners, BioAdvance, Palo Alto Investors, Third Point Ventures, and Vivo Ventures.[2] This funding trajectory demonstrated investor confidence in the company's drug development approach and market opportunity.
Ceptaris exemplifies the specialty pharmaceutical model—focusing on rare diseases and niche patient populations where unmet medical needs create market opportunities despite smaller patient bases. The company's acquisition by Actelion in 2013 reflects how larger pharmaceutical companies strategically acquire specialized biotech firms to expand their rare disease portfolios and accelerate market entry for novel formulations.
As a subsidiary of Actelion (now part of Johnson & Johnson following Actelion's acquisition), Ceptaris's independent trajectory concluded with its 2013 acquisition. The company's legacy demonstrates how venture-backed specialty pharma companies can achieve successful exits by solving specific clinical problems in rare disease spaces—a model that continues to attract investment in the biotech ecosystem today.
Ceptaris Therapeutics has raised $54.0M across 4 funding rounds. Most recently, it raised $10.0M Series D in June 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2012 | $10.0M Series D | Frazier Healthcare Partners, Aperture Venture Partners, BioAdvance, Burrill & Company, Osage Venture Partners, Palo Alto Investors, Third Point, Vivo Ventures | |
| Feb 21, 2012 | $15.0M Debt | Oxford Finance, Silicon Valley Bank | |
| Aug 1, 2011 | $14.0M Series D | Frazier Healthcare Partners, Aperture Venture Partners, Burrill & Company, Palo Alto Investors, Vivo Ventures | |
| Nov 1, 2007 | $15.0M Series C | Frazier Healthcare Partners |